Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $104 | $70 | $67 | $103 |
| - Cash | $47 | $37 | $30 | $36 |
| + Debt | $4 | $30 | $29 | $30 |
| Enterprise Value | $60 | $64 | $65 | $97 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$25 | -$40 | -$28 | -$36 |
| % Margin | – | – | – | – |
| Net Income | -$26 | -$41 | -$29 | -$37 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.44 | -0.68 | -0.48 | -0.62 |
| % Growth | 35.3% | -41.7% | 22.6% | – |
| Operating Cash Flow | -$30 | -$32 | -$34 | -$27 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$30 | -$32 | -$34 | -$27 |